**2. PARPis and clinical trials**

Currently, three PARPis are approved for the treatment of EOC: olaparib, rucaparib, and niraparib. All these drugs are available for the management of recurrent disease as monotherapies, whereas only olaparib and niraparib are approved as frontline maintenance options after a response to platinum-based chemotherapy. Lastly, olaparib is the only approved drug in combination with bevacizumab as a firstline maintenance strategy for a subset of patients whose cancer is associated with HRD status (**Table 1**).
